Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies
AbstractObjective To investigate the effect of antimalarials on cancer risk in patients with systemic lupus erythematosus (SLE).Methods PubMed, EMBASE, Web of Science, and the Cochrane Library were searched from their inception to October 3, 2020. Relative risk (RR) with 95% confidence intervals (CI...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2021.1981547 |
| _version_ | 1797385697634549760 |
|---|---|
| author | Xian-Bao Li Nv-Wei Cao Xiu-Jie Chu Hao-Yue Zhou Hua Wang Si-Jie Yu Dong-Qing Ye Bao-Zhu Li |
| author_facet | Xian-Bao Li Nv-Wei Cao Xiu-Jie Chu Hao-Yue Zhou Hua Wang Si-Jie Yu Dong-Qing Ye Bao-Zhu Li |
| author_sort | Xian-Bao Li |
| collection | DOAJ |
| description | AbstractObjective To investigate the effect of antimalarials on cancer risk in patients with systemic lupus erythematosus (SLE).Methods PubMed, EMBASE, Web of Science, and the Cochrane Library were searched from their inception to October 3, 2020. Relative risk (RR) with 95% confidence intervals (CI) was used to evaluate the results. Subgroup analyses were used to assess heterogeneity. A funnel plot was used to explore publication bias. STATA was applied for all analyses.Results A total of nine studies consisted of four nested case–control, two case–cohort and three cohort studies were included. The results showed that antimalarials might reduce the risk of cancer in SLE (RR = 0.68, 95%CI: 0.55–0.85). In the subgroup analysis of four nested case–control and two case–cohort studies, the pooled RR was estimated as 0.69 (95% CI: 0.60–0.80). In four studies about hydroxychloroquine, the pooled RR was estimated as 0.70 (95% CI: 0.53–0.93). Antimalarials might reduce the risk of cancer in SLE among the Asian population (RR = 0.66; 95% CI: 0.49–0.88) (I2 = 43.1%, p = .173). And the consistent result was also found in SLE from multiple centres (RR = 0.72; 95%CI: 0.60–0.87) (I2 = 0%, p = .671). On disease course- and comorbidities-matched studies, the pooled RRs were 0.69 (95% CI: 0.52–0.93) and 0.59 (95% CI: 0.46–0.75), respectively.Conclusion Results of this meta-analysis showed that antimalarial drugs might be protective factors for cancer in SLE. Hydroxychloroquine might be a protective factor for cancer in SLE patients.KEY MESSAGESAntimalarials might be protective factors for cancer in SLE.Hydroxychloroquine might be a protective factor for cancer in SLE patients.The first article to perform the meta-analysis of antimalarial drugs on the risk of cancer in SLE patients. |
| first_indexed | 2024-03-08T21:58:02Z |
| format | Article |
| id | doaj.art-6e9f45582e814a148e766a39027174d3 |
| institution | Directory Open Access Journal |
| issn | 0785-3890 1365-2060 |
| language | English |
| last_indexed | 2024-03-08T21:58:02Z |
| publishDate | 2021-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj.art-6e9f45582e814a148e766a39027174d32023-12-19T16:46:26ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602021-01-015311688169610.1080/07853890.2021.1981547Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studiesXian-Bao Li0Nv-Wei Cao1Xiu-Jie Chu2Hao-Yue Zhou3Hua Wang4Si-Jie Yu5Dong-Qing Ye6Bao-Zhu Li7Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, ChinaDepartment of Clinical Medicine “5 + 3” Integration, Second Clinical Medical College, Anhui Medical University, Hefei, Anhui, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, ChinaAbstractObjective To investigate the effect of antimalarials on cancer risk in patients with systemic lupus erythematosus (SLE).Methods PubMed, EMBASE, Web of Science, and the Cochrane Library were searched from their inception to October 3, 2020. Relative risk (RR) with 95% confidence intervals (CI) was used to evaluate the results. Subgroup analyses were used to assess heterogeneity. A funnel plot was used to explore publication bias. STATA was applied for all analyses.Results A total of nine studies consisted of four nested case–control, two case–cohort and three cohort studies were included. The results showed that antimalarials might reduce the risk of cancer in SLE (RR = 0.68, 95%CI: 0.55–0.85). In the subgroup analysis of four nested case–control and two case–cohort studies, the pooled RR was estimated as 0.69 (95% CI: 0.60–0.80). In four studies about hydroxychloroquine, the pooled RR was estimated as 0.70 (95% CI: 0.53–0.93). Antimalarials might reduce the risk of cancer in SLE among the Asian population (RR = 0.66; 95% CI: 0.49–0.88) (I2 = 43.1%, p = .173). And the consistent result was also found in SLE from multiple centres (RR = 0.72; 95%CI: 0.60–0.87) (I2 = 0%, p = .671). On disease course- and comorbidities-matched studies, the pooled RRs were 0.69 (95% CI: 0.52–0.93) and 0.59 (95% CI: 0.46–0.75), respectively.Conclusion Results of this meta-analysis showed that antimalarial drugs might be protective factors for cancer in SLE. Hydroxychloroquine might be a protective factor for cancer in SLE patients.KEY MESSAGESAntimalarials might be protective factors for cancer in SLE.Hydroxychloroquine might be a protective factor for cancer in SLE patients.The first article to perform the meta-analysis of antimalarial drugs on the risk of cancer in SLE patients.https://www.tandfonline.com/doi/10.1080/07853890.2021.1981547Systemic lupus erythematosuscancerantimalarialshydroxychloroquine |
| spellingShingle | Xian-Bao Li Nv-Wei Cao Xiu-Jie Chu Hao-Yue Zhou Hua Wang Si-Jie Yu Dong-Qing Ye Bao-Zhu Li Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies Annals of Medicine Systemic lupus erythematosus cancer antimalarials hydroxychloroquine |
| title | Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies |
| title_full | Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies |
| title_fullStr | Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies |
| title_full_unstemmed | Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies |
| title_short | Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies |
| title_sort | antimalarials may reduce cancer risk in patients with systemic lupus erythematosus a systematic review and meta analysis of prospective studies |
| topic | Systemic lupus erythematosus cancer antimalarials hydroxychloroquine |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2021.1981547 |
| work_keys_str_mv | AT xianbaoli antimalarialsmayreducecancerriskinpatientswithsystemiclupuserythematosusasystematicreviewandmetaanalysisofprospectivestudies AT nvweicao antimalarialsmayreducecancerriskinpatientswithsystemiclupuserythematosusasystematicreviewandmetaanalysisofprospectivestudies AT xiujiechu antimalarialsmayreducecancerriskinpatientswithsystemiclupuserythematosusasystematicreviewandmetaanalysisofprospectivestudies AT haoyuezhou antimalarialsmayreducecancerriskinpatientswithsystemiclupuserythematosusasystematicreviewandmetaanalysisofprospectivestudies AT huawang antimalarialsmayreducecancerriskinpatientswithsystemiclupuserythematosusasystematicreviewandmetaanalysisofprospectivestudies AT sijieyu antimalarialsmayreducecancerriskinpatientswithsystemiclupuserythematosusasystematicreviewandmetaanalysisofprospectivestudies AT dongqingye antimalarialsmayreducecancerriskinpatientswithsystemiclupuserythematosusasystematicreviewandmetaanalysisofprospectivestudies AT baozhuli antimalarialsmayreducecancerriskinpatientswithsystemiclupuserythematosusasystematicreviewandmetaanalysisofprospectivestudies |